Takeda Pharmaceutical Company Limited

Polaris Group

Philip Erickson

John David Lawson

Mallareddy Komandla

Shaosong Chu

Jeffrey Alan Stafford

Michael Brennan Wallace

Jun Feng

Zhe Nie

Zacharia S Cheruvallath

Christopher McBride

Zhiyuan Zhang

Mingnam Tang

Joanne Miura

Jerome C Bressi

Sean Timothy Murphy

Lily Kwok

Huong-Thu Ton-Nu

Sanjib Das

Carin L Perretta

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Indazole derivatives

Compounds of the following formula are provided for use with cMET: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the compounds.

cMET inhibitors

Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds.

Protein kinase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Philip Erickson